{
  "trial_id": "NCT00741819",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, PAH diagnosis category, baseline six-minute walk distance (6MWD), current Ventavis dose, use of background therapy (endothelin receptor antagonist or phosphodiesterase-5-inhibitor), previous right heart catheterization results, previous echocardiography results.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Pulmonary Arterial Hypertension (PAH) etiology",
          "PAH diagnosis category"
        ],
        [
          "Six-minute walk distance (6MWD)",
          "baseline six-minute walk distance (6MWD)"
        ],
        [
          "Background PAH therapy",
          "use of background therapy (endothelin receptor antagonist or phosphodiesterase-5-inhibitor)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "N-terminal prohormone brain natriuretic peptide (NT-proBNP)"
      ],
      "remaining_candidate_features": [
        "current Ventavis dose",
        "previous right heart catheterization results",
        "previous echocardiography results."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline six-minute walk distance (6MWD), PAH diagnosis category, Background therapy usage, Duration of Ventavis therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Pulmonary Arterial Hypertension (PAH) etiology",
          "PAH diagnosis category"
        ],
        [
          "Background PAH therapy",
          "Background therapy usage"
        ],
        [
          "Six-minute walk distance (6MWD)",
          "Baseline six-minute walk distance (6MWD)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "N-terminal prohormone brain natriuretic peptide (NT-proBNP)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Duration of Ventavis therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, PAH diagnosis, Six-minute walk distance, Background therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Pulmonary Arterial Hypertension (PAH) etiology",
          "PAH diagnosis"
        ],
        [
          "Background PAH therapy",
          "Background therapy"
        ],
        [
          "Six-minute walk distance (6MWD)",
          "Six-minute walk distance"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "N-terminal prohormone brain natriuretic peptide (NT-proBNP)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), PAH etiology (idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts, associated with collagen vascular disease, associated with HIV, associated with appetite suppressant/toxin use), six-minute walk distance (6MWD), background therapy (endothelin receptor antagonist, phosphodiesterase-5-inhibitor, or both), duration of PAH diagnosis, duration of Ventavis treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Pulmonary Arterial Hypertension (PAH) etiology",
          "PAH etiology (idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts, associated with collagen vascular disease, associated with HIV, associated with appetite suppressant/toxin use)"
        ],
        [
          "Six-minute walk distance (6MWD)",
          "six-minute walk distance (6MWD)"
        ],
        [
          "Background PAH therapy",
          "background therapy (endothelin receptor antagonist, phosphodiesterase-5-inhibitor, or both)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "N-terminal prohormone brain natriuretic peptide (NT-proBNP)"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "weight",
        "height",
        "body mass index (BMI)",
        "duration of PAH diagnosis",
        "duration of Ventavis treatment."
      ]
    }
  }
}